within Pharmacolibrary.Drugs.ATC.N;

model N05AX17
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.74,
    Cl             = 0.00045,
    adminDuration  = 600,
    adminMass      = 34 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 2.173,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00635,
    Tlag           = 10.200000000000001,            
    Vdp             = 1.59,
    k12             = 528,
    k21             = 528
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AX17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pimavanserin is an atypical antipsychotic agent, acting as a selective serotonin 5-HT2A receptor inverse agonist. It is primarily used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The drug is approved by the FDA and is currently in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects following oral administration.</p><h4>References</h4><ol><li><p>Wu, W, et al., &amp; Chen, X (2018). Investigation of metabolic profile of pimavanserin in rats by ultrahigh-performance liquid chromatography combined with Fourier transform ion cyclotron resonance mass spectrometry. <i>Rapid communications in mass spectrometry : RCM</i> 32(3) 269–276. DOI:<a href=&quot;https://doi.org/10.1002/rcm.8025&quot;>10.1002/rcm.8025</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29105858/&quot;>https://pubmed.ncbi.nlm.nih.gov/29105858</a></p></li><li><p>Vanover, KE, et al., &amp; Weiner, DM (2007). Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. <i>Journal of clinical pharmacology</i> 47(6) 704–714. DOI:<a href=&quot;https://doi.org/10.1177/0091270007299431&quot;>10.1177/0091270007299431</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17473118/&quot;>https://pubmed.ncbi.nlm.nih.gov/17473118</a></p></li><li><p>Wang, S, et al., &amp; Chen, X (2017). Development of a UPLC-MS/MS method for determination of pimavanserin tartrate in rat plasma: Application to a pharmacokinetic study. <i>Journal of pharmaceutical analysis</i> 7(6) 406–410. DOI:<a href=&quot;https://doi.org/10.1016/j.jpha.2017.07.004&quot;>10.1016/j.jpha.2017.07.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29404067/&quot;>https://pubmed.ncbi.nlm.nih.gov/29404067</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AX17;
